Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telitacicept (Primary)
  • Indications Sjogren's syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms UPSTREAM
  • Sponsors Vor Biopharma

Most Recent Events

  • 12 Feb 2026 Status changed from planning to not yet recruiting.
  • 26 Dec 2025 New trial record
  • 15 Dec 2025 According to a Vor Biopharma media release, the company has secured a financing of approximately $150 million by selling its shares. Vor Bio intends to use it for the initiation of a global Phase 3 clinical trial in primary Sjogren's disease.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top